# EDGAR Filing Document

**Accession Number:** 0001581178
**File Stem:** 0001193125-26-108982
**Filing Date:** 2026-3
**Character Count:** 7271
**Document Hash:** ffc33d6b9d56c4aa800073ee313935d2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-108982.hdr.sgml**: 20260316

**ACCESSION NUMBER**: 0001193125-26-108982

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260316

**DATE AS OF CHANGE**: 20260316

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** EUPRAXIA PHARMACEUTICALS INC.
- **CENTRAL INDEX KEY:** 0001581178
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-94690
- **FILM NUMBER:** 26758867

**BUSINESS ADDRESS:**
- **STREET 1:** 201-2067 CADBORO BAY RD.
- **CITY:** VICTORIA
- **STATE:** A1
- **ZIP:** V8R 5G4
- **BUSINESS PHONE:** 250-590-3968

**MAIL ADDRESS:**
- **STREET 1:** 201-2067 CADBORO BAY RD.
- **CITY:** VICTORIA
- **STATE:** A1
- **ZIP:** V8R 5G4
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Freedman Joseph S.
- **CENTRAL INDEX KEY:** 0002043590

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 27 SWANSDOWN DRIVE
- **CITY:** NORTH YORK
- **STATE:** A6
- **ZIP:** M2L 2N2

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**Eupraxia Pharmaceuticals Inc.**

*(Name of Issuer)*

**Common Shares, no par value**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Gavin Froehlich**<br>201-2067 Cadboro Bay Road<br>Victoria, British Columbia Z4 V8R 5G4<br>778-763-1682

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**03/13/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Joseph S. Freedman** | Name of reporting person<br>**Joseph S. Freedman** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**—** | Citizenship or place of organization<br>**—** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**4309205.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1534010.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**4309205.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1534010.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**5843215.00** | Aggregate amount beneficially owned by each reporting person<br>**5843215.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.0%** | Percent of class represented by amount in Row (11)<br>**9.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** (1)  Rows 7 through 11 include (a) 1,699,157 of the Issuer's (as defined below) common shares, with no par value (the "Common Shares") and 1,493,985 Common Shares underlying Issuer's Series 1 preferred shares, with no par value (the "Preferred Shares") held by Joseph S. Freedman; (b) 334,010 Common Shares and 1,200,000 Common Shares underlying Preferred Shares held by Mr. Freedman's spouse; (c) options to purchase 155,000 Common Shares (the "Option Shares") which are both owned by and exercisable within sixty (60) days at the discretion of Mr. Freedman; (d) 10,000 Common Shares underlying restricted stock units (the "RSU Shares") which are both owned and exercisable within sixty (60) days at the discretion of Mr. Freedman; (e) 387,300 Common Shares and 460,000 Common Shares underlying Preferred Shares owned by a trust for which Mr. Freedman serves as the sole trustee; and (f) 103,763 Common Shares held by the minor children of Mr. Freedman. Mr. Freedman disclaims beneficial ownership of the Common Shares held by his minor children.
(2)  Row 13 is calculated based on the Common Shares, Preferred Shares, Option Shares and RSU Shares, beneficially owned by the Reporting Person relative to the Issuer's 61,503,180 outstanding Common Shares, as of March 13 2026, as reported in the Issuer's Annual Report on Form 40-F for the fiscal year ended December 31, 2025, filed with the SEC on March 13, 2026, plus the 3,153,985 Preferred Shares, 155,000 Option Shares and 10,000 RSU Shares.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Shares, no par value

**(b) Name of Issuer:**
Eupraxia Pharmaceuticals Inc.

**(c) Address of Issuer's Principal Executive Offices:**
201-2067 Cadboro Bay Road, Victoria, British Columbia, Z4, V8R 5G4

The following constitutes Amendment No. 2 ("Amendment No. 2") to the Schedule 13D filed with the Securities and Exchange Commission on November 7, 2024 and amended on September 26, 2025 (as amended, the "Schedule 13D") by Joseph S. Freedman (the "Reporting Person"). This Amendment No. 1 supplements Item 3 and amends and restates Items 5 as set forth below. Capitalized terms used herein and not otherwise defined in this Amendment No. 2 have the meanings set forth in the Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5 is hereby amended and restated to read as follows: See rows (11) and (13) of the cover page to this Schedule 13D for the aggregate number of Common Shares, Preferred Shares, Option Shares and RSU Shares and percentage of Common Shares beneficially owned by the Reporting Person.

**(b)**
See rows (7) through (10) of the cover page to this Schedule 13D for the Common Shares, Preferred Shares, Option Shares and RSU Shares as to which the Reporting Person has the sole power to vote or direct the vote and sole power to dispose or to direct the disposition thereof.

**(c)**
Other than as described in Item 3, the Reporting Person has not effected any transactions involving Common Shares in the 60 days prior to filing this Schedule 13D.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Joseph S. Freedman

**Signature:** /s/ Joseph S. Freedman

**Name/Title:** Joseph S. Freedman

**Date:** 03/16/2026